CLINICAL TRIALS PROFILE FOR GLEEVEC
✉ Email this page to a colleague
All Clinical Trials for GLEEVEC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00015834 ↗ | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2001-05-01 | Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells |
| NCT00022737 ↗ | Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | Completed | National Cancer Institute (NCI) | Phase 3 | 2002-10-01 | This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. |
| NCT00025246 ↗ | Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-09-01 | This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth |
| NCT00025415 ↗ | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | Completed | National Cancer Institute (NCI) | Phase 1 | 2001-08-01 | Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction |
| NCT00026169 ↗ | Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure | Completed | National Cancer Institute (NCI) | Phase 1 | 2001-09-01 | Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure. Imatinib mesylate may stop the growth of cancer cells by stopping the enzyme necessary for cancer cell growth. Kidney failure may delay the elimination of imatinib mesylate from the body, which may lead to longer drug exposure and increase toxic side effects |
| NCT00027586 ↗ | Imatinib Mesylate in Treating Patients With Metastatic Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-09-01 | RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma. |
| NCT00027586 ↗ | Imatinib Mesylate in Treating Patients With Metastatic Melanoma | Completed | M.D. Anderson Cancer Center | Phase 2 | 2001-09-01 | RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLEEVEC
Condition Name
Clinical Trial Locations for GLEEVEC
Trials by Country
Clinical Trial Progress for GLEEVEC
Clinical Trial Phase
Clinical Trial Sponsors for GLEEVEC
Sponsor Name
